Please Wait
Applying Filters...
menu
    • menu
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Addyi (TN)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 915Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    PHIL And Sprout Pharma Enhance Addyi Access Program
    PHIL And Sprout Pharma Enhance Addyi Access Program

    08 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/phil-and-sprout-pharmaceuticals-expand-their-affordable-direct-to-patient-access-program-for-addyiflibanserin-302655793.html

    PR NEWSWIRE
    08 Jan 2026
    Share Share
    FDA Approves Addyi For Postmenopausal Women's Sexual Health
    FDA Approves Addyi For Postmenopausal Women's Sexual Health

    15 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/historic-first-in-womens-sexual-health-fda-grants-approval-for-addyi-flibanserin-in-postmenopausal-women-302642397.html

    PR NEWSWIRE
    15 Dec 2025
    Share Share
    Addyi® Celebrates 10 Years Leading Women's Sexual Health
    Addyi® Celebrates 10 Years Leading Women's Sexual Health

    04 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/addyi-marks-a-decade-of-leadership-in-womens-sexual-health-302546088.html

    PR NEWSWIRE
    04 Sep 2025
    Share Share
    FDA Prioritizes Addyi® for Low Desire in Postmenopausal Women
    FDA Prioritizes Addyi® for Low Desire in Postmenopausal Women

    24 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-grants-priority-review-for-addyi-flibanserin-paving-the-way-for-expanded-access-to-treat-low-sexual-desire-in-postmenopausal-women-302512883.html

    PR NEWSWIRE
    24 Jul 2025
    Share Share
    FDA Warns Sprout Over Addyi Instagram Post, Lacking Ind
    FDA Warns Sprout Over Addyi Instagram Post, Lacking Ind

    11 Jun 2025

    // RAPS

    https://www.raps.org/news-and-articles/news-articles/2025/6/fda-warns-sprout-over-addyi-instagram-post,-clinic

    RAPS
    11 Jun 2025
    Share Share
    Sprout Announces Release of Abstract Reporting Positive Results for Flibanserin
    Sprout Announces Release of Abstract Reporting Positive Results for Flibanserin

    02 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sprout-pharmaceuticals-announces-release-of-abstract-reporting-positive-interim-results-for-flibanserin-in-breast-cancer-patients-suffering-from-low-libido-for-poster-discussion-at-2023-asco-annual-meeting-301840912.html

    PR NEWSWIRE
    02 Jun 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.